THOMAS MONATH to Disease Models, Animal
This is a "connection" page, showing publications THOMAS MONATH has written about Disease Models, Animal.
Connection Strength
0.615
-
rVSV?G-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model. Viruses. 2025 Feb 28; 17(3).
Score: 0.113
-
Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential. PLoS Pathog. 2022 06; 18(6):e1010658.
Score: 0.094
-
Comparative evaluation of pathogenicity of three isolates of vesicular stomatitis virus (Indiana serotype) in pigs. J Gen Virol. 2019 11; 100(11):1478-1490.
Score: 0.078
-
Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Viruses. 2013 Dec 09; 5(12):3048-70.
Score: 0.052
-
Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine. 2011 Aug 11; 29(35):6008-16.
Score: 0.044
-
Treatment of yellow fever. Antiviral Res. 2008 Apr; 78(1):116-24.
Score: 0.034
-
Pathogenesis and pathophysiology of yellow fever. Adv Virus Res. 2003; 60:343-95.
Score: 0.024
-
Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease. Am J Trop Med Hyg. 2022 11 14; 107(5):1091-1098.
Score: 0.024
-
Prospects for development of a vaccine against the West Nile virus. Ann N Y Acad Sci. 2001 Dec; 951:1-12.
Score: 0.023
-
Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases. Vaccine. 2019 10 08; 37(43):6248-6254.
Score: 0.019
-
Intranasal antibody prophylaxis for protection against viral disease. Clin Microbiol Rev. 1999 Jul; 12(3):383-93.
Score: 0.019
-
Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology. 1999 May 10; 257(2):363-72.
Score: 0.019
-
Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector. Clin Vaccine Immunol. 2017 Jan; 24(1).
Score: 0.016
-
Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J Infect Dis. 1996 Aug; 174(2):256-61.
Score: 0.016
-
Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice. Vaccine. 2012 Jan 05; 30(2):254-64.
Score: 0.011
-
A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirus. Virology. 2007 Jun 05; 362(2):468-74.
Score: 0.008
-
Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology. 2001 Nov 25; 290(2):309-19.
Score: 0.006
-
Formulations of single or multiple H. pylori antigens with DC Chol adjuvant induce protection by the systemic route in mice. Optimal prophylactic combinations are different from therapeutic ones. FEMS Immunol Med Microbiol. 2001 Mar; 30(2):157-65.
Score: 0.005
-
Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun. 1999 Feb; 67(2):527-38.
Score: 0.005
-
Experimentally induced infection with Helicobacter pylori in squirrel monkeys (Saimiri spp.): clinical, microbiological, and histopathologic findings. Lab Anim Sci. 1998 Jun; 48(3):303-9.
Score: 0.004
-
Effect of human gamma interferon on yellow fever virus infection. Am J Trop Med Hyg. 1988 May; 38(3):647-50.
Score: 0.002